Business Wire

JT-GROUP

14.12.2022 07:02:43 CET | Business Wire | Press release

Share
JT Group Recognized on CDP’s “Climate Change A List” for the 4th Consecutive Year

Japan Tobacco Inc. (JT) (TSE: 2914) has once again been recognized for its leadership in corporate sustainability by the global environmental non-profit organization CDP. JT achieved a place on CDP's prestigious "A List"1 for tackling climate change for the fourth consecutive year.

JT is one of 283 companies in the world and 74 companies in Japan that were included on the "Climate Change A List", out of more than 15,000 companies participating in the CDP environmental disclosure program in 2022. This marks JT's fifth recognition for climate change following 2016, 2019, 2020 and 2021.

In 2019, the JT Group launched the “JT Group Environment Plan 2030”, reflecting changes in its business environment, with energy and emissions, natural resources and waste as key focus areas. Specific examples of measures the Group is taking to reduce its contribution to climate change, include the introduction of renewable energy and the reduction of greenhouse gas emissions from business activities as well as from the raw materials and services it purchases.

Hisato Imokawa, Senior Vice President, Chief Sustainability Officer, said:
"We are honored that JT has been included on the CDP’s 'Climate Change A List' for the fourth consecutive year. This inclusion reflects our continued efforts to reduce our environmental footprint and expand our transparency in disclosing information. As a leading international company, we believe that addressing global environmental concerns, especially those relating to climate change, forms the basis of our business management.
In February 2022, we updated our targets for ’Energy and Emissions’ in the ‘JT Group Environment Plan 2030’, aiming to achieve carbon neutrality by 2030 and Net-Zero greenhouse gas emissions across our entire value chain by 2050. 
The JT Group will continue to contribute to the sustainable development of society by further fulfilling our responsibility to the environment and maintaining the trust of our stakeholders.”
JT Group’s 2030 Greenhouse Gas (GHG) reduction targets in relation to Scope 1, 2 and 3 emissions have been deemed to be in conformance with the criteria set by the Science Based Targets Initiative (SBTi).

Society’s interest in ESG and its demands on companies are increasing year by year, and it is essential for companies to work on improving their sustainability initiatives, to ensure continuous growth. In light of this, the JT Group has placed sustainability at the forefront of its management agenda, and our employees are working hand-in-hand to address ESG issues. To ensure that a healthy and sustainable environment is passed on to future generations, the JT Group is committed to achieving a balance between corporate activities and environment preservation by addressing environmental challenges in wider society as well as in the Group’s value chain.

About CDP
CDP (HQ: London) is the leading international non-profit organization that accelerates action to achieve sustainable economies, assessing disclosure and actions by companies from around the world. Representing over 680 investors with assets of USD 131 trillion, CDP sends out questionnaires to companies listed on stock exchanges worldwide, asking them about their activities for reducing greenhouse gas emissions and safeguarding water resources, then evaluates the answers and publishes the scores.

1 CDP scores companies from D- to A based on their environmental performance, which starts with disclosure, and progresses to awareness, management, and finally to leadership. CDP's A List recognizes the world's companies leading on environmental performance.

###

Japan Tobacco Inc. is a leading international tobacco company with operations in more than 130 countries and regions. With approximately 55,000 employees, it manufactures and sells some of the world’s best-known brands including Winston, Camel, MEVIUS and LD. The JT Group is committed to investing in Reduced-Risk Products (RRP) and currently markets its heated tobacco products under its Ploom brand and various e-cigarette products under its Logic brand. The Group is also present in the pharmaceutical and processed food businesses. For more information, visit https://www.jt.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005606/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye